G

Genmab

Develops and licenses antibody cancer therapeutics

Drug Safety and Pharmacovigilance Scientist - Global

Full-Time
$162.6k - $244k/yr+ Discretionary bonuses + Long-term incentives + 401(k) match
Senior
PharmD
Princeton, NJ, USA
HybridHybrid work arrangement.
Biology & Biotech

About the job

Requirements
  • A Health Care Professional degree is required, such as Registered Nurse/Bachelor of Science in Nursing/Master of Science in Nursing, Nurse Practitioner, Physician Assistant, or Doctor of Pharmacy, along with at least five years of pharmaceutical industry experience in drug safety and pharmacovigilance as a Safety Scientist in clinical trial and post-marketing environments.
  • Experience authoring safety signal assessment reports, Development Safety Update Reports, Periodic Benefit-Risk Evaluation Reports, Risk Management Plans, and Reference Safety Information.
  • Skill in signal detection processes and managing safety information from clinical development and post-marketing sources.
  • Experience with Food and Drug Administration and European Medicines Agency regulations and International Council for Harmonisation guidance governing pharmacovigilance and risk management.
  • Knowledge of the drug development process, pharmacovigilance databases, and Medical Dictionary for Regulatory Activities coding.
  • Experience using safety databases, preferably the Argus Safety Database.
  • Documented experience overseeing multiple trials with safety inputs at the global level.
  • International experience in a similar role with internal and external stakeholders.
  • Excellent written and spoken English communication skills.
  • Ability to build professional relationships with collaborators and business partners, prioritize work in a fast-paced and changing environment, and contribute to organizational goals.
Responsibilities
  • Contribute to the development of safety strategies and safety deliverables for assigned programs in collaboration with Global Drug Safety and Pharmacovigilance and cross-functional stakeholders.
  • Perform ongoing surveillance, including signal detection and evaluation, of clinical trials and post-marketing safety data.
  • Serve as the primary safety contact for other departments and ensure timely handling of safety issues for assigned trials and programs.
  • Provide safety review and input for trial protocols, electronic and paper case report forms, trial master files, Investigator’s Brochures, and Subject Informed Consent documents.
  • Contribute to health authority requests and review key submission documents.
  • Contribute to safety-related documents throughout the product lifecycle, including safety assessment reports, Reference Safety Information in Investigator’s Brochures, adverse drug reactions in Company Core Data Sheets and product labels, aggregate safety reports such as Development Safety Update Reports, Periodic Benefit-Risk Evaluation Reports, Periodic Safety Update Reports, and Periodic Adverse Event Reports, Risk Management Plans, and responses to internal and external safety-information requests.
  • Contribute to planning and conducting Safety Committee activities and Data Monitoring Committees.
  • Conduct safety training for employees, contract research organizations, investigators, and other relevant site personnel.
  • Contribute to multidisciplinary project groups, including Clinical Management Teams for assigned products.
  • Contribute to developing and optimizing tools and processes.
  • Interact with safety and clinical contract research organizations, perform sponsor oversight for safety-related tasks, process invoices, and ensure regulatory compliance and reporting requirements for assigned products.
  • Support review of Safety Data Exchange Agreements with partners.
  • Collaborate with external experts and partners.
  • Monitor new and updated regulations and guidelines and assess their impact on drug safety processes.
  • Ensure compliance with regulatory guidelines and internal processes in preparation for audits and inspections.
  • Participate in audit and inspection activities as required.
Desired Qualifications
  • Experience in oncology and/or first-in-human trials.

About the company

Genmab develops antibody-based therapies to treat cancer. The company discovers, develops, and commercializes proprietary antibody technologies and treatments designed to target and kill cancer cells, often in collaboration with other biotech or pharmaceutical partners. Its products work by using antibodies that recognize specific cancer cell markers, helping the immune system or the drugs attack and destroy those cells. Genmab differentiates itself through its own patented antibody platforms and its focus on strategically partnering for development and commercialization, allowing it to leverage scientific expertise and shared resources rather than relying on a single product. The company aims to turn scientific insights into approved cancer medicines that improve patient outcomes while building value through licensing deals and collaborations with researchers and drug developers around the world.

Company Size

1,001-5,000

Company Stage

IPO

Headquarters

Copenhagen, Denmark

Founded

1999

Get referred to Genmab

See people who can refer or advise you

Simplify Jobs

Simplify's Take

What believers are saying

  • August 6, 2026 Genmab raised 2026 revenue guidance to $4.325-$4.525 billion.
  • European Commission approved TEPKINLY on July 6, 2026, expanding epcoritamab's lymphoma franchise.
  • Merus deal adds petosemtamab, giving Genmab a deeper solid-tumor pipeline starting 2026.

What critics are saying

  • July 23, 2026 EPCORE DLBCL-1 missed U.S. overall survival, weakening epcoritamab's expansion story.
  • Genmab carries about $5.2 billion borrowings after the 2025 Merus acquisition.
  • DARZALEX royalty growth eventually fades after 2029; pipeline failures then hit the business hard.

What makes Genmab unique

  • Genmab monetizes royalty-heavy oncology franchises, especially DARZALEX and Kesimpta, funding R&D.
  • Its DuoBody platform produced epcoritamab, EPKINLY, and several next-generation bispecific programs.
  • Genmab commercializes Tivdak independently outside the United States, proving real launch capability.

Help us improve and share your feedback! Did you find this helpful?

Benefits

401(k) Retirement Plan

Health Insurance

Dental Insurance

Vision Insurance

Life Insurance

Disability Insurance

Health Savings Account/Flexible Spending Account

Unlimited Paid Time Off

Flexible Work Hours

Remote Work Options

Paid Vacation

Paid Sick Leave

Paid Holidays

Hybrid Work Options

Stock Options

Company Equity

Performance Bonus

Profit Sharing

Employee Stock Purchase Plan

Relocation Assistance

Parental Leave

Family Planning Benefits

Fertility Treatment Support

Adoption Assistance

Childcare Support

Elder Care Support

Pet Insurance

Bereavement Leave

Professional Development Budget

Conference Attendance Budget

Tuition Reimbursement

Mentorship Program

Wellness Program

Mental Health Support

Gym Membership

Commuter Benefits

Phone/Internet Stipend

Home Office Stipend

Legal Services

Employee Discounts

Company Social Events

Growth & Insights and Company News

Headcount

6 month growth

0%

1 year growth

0%

2 year growth

-1%
Associated Press
Oct 13th, 2026
Darzalex net sales hit $4.2B in Q3 2026, with $2.5B from the US

Genmab said worldwide net sales of its cancer drug DARZALEX reached $4,239 million in the third quarter of 2026, as reported by Johnson & Johnson (J&J). The Copenhagen-based biotech announced the figure on October 13, 2026. Sales in the US were $2,528 million, while the rest of the world accounted for $1,711 million. The total includes the subcutaneous version, sold as DARZALEX FASPRO in the US. Genmab receives royalties on worldwide sales of both the intravenous and subcutaneous products. J&J holds an exclusive worldwide licence to develop, manufacture, and commercialise daratumumab, the drug's active ingredient.

Finans
Oct 6th, 2026
Genmab investors on cloud nine after promising data - stock sees biggest gain in six years.

Genmab investors on cloud nine after promising data - stock sees biggest gain in six years. Oct. 6, 2026 at 15:40 MarketWire There is a tailwind on the bike path for Genmab on Tuesday, as the stock advances, analysts raise their price targets in droves, and the market value rises by DKK 13 billion to DKK 161 billion an hour and a half before the stock exchange's closing time. The share price gain is 9 percent to DKK 2,587 - and it is the biggest single-day price increase in more than six years. It is the results from Genmab and the partner... Written for companies. By those who know them Finans Kvartal Subscription for one user Unlimited access for 3 months Annual price: DKK 5,180 Finans Årlig Subscription for one user Save DKK 680 Unlimited access for 12 months Annual price: DKK 4,500 Finans Business Subscription for multiple users Finans Business is for businesses that want a tailored solution with multiple accesses combined in one subscription. Payment options Try Finans for 30 days - and get access to all content. Order access

Finans
Oct 5th, 2026
Genmab tops red C25 after study data.

Genmab tops red C25 after study data. Oct. 5, 2026 at 11:56 MarketWire Genmab took the top spot in the Danish elite index on Monday after positive trial data for a new drug candidate, while upward revisions are helping send ChemoMetec and Alm. Brand higher among the small-cap stocks. - It is a market without any major swings compared to Friday. Not much has happened over the weekend, so the things that were in focus... Written for companies. By those who know them Finans Quarterly Subscription for one user Unlimited access for 3 months Annual price: DKK 5,180 Finans Annual Subscription for one user Save DKK 680 Unlimited access for 12 months Annual price: DKK 4,500 Finans Business Subscription for multiple users Finans Business is for companies that want a tailor-made solution with multiple accesses combined in a single subscription. Payment options Try Finans for 30 days - and get access to all content. Order access

Yahoo Finance
Aug 13th, 2026
Genmab raises 2026 revenue guidance to $4.5B despite epcoritamab setback; AbbVie reports $17B Q2 revenue

Genmab and AbbVie confirmed on 23 July that their jointly developed bispecific antibody epcoritamab failed to meet its primary endpoint in a Phase 3 trial. The study evaluated epcoritamab monotherapy against chemoimmunotherapy in transplant-ineligible adults with relapsed/refractory diffuse large B-cell lymphoma. In the US, where overall survival was the sole primary endpoint, the trial did not demonstrate statistically significant improvement. Despite the setback, epcoritamab maintains its accelerated FDA approval. Both companies will review the full data set with regulators to determine next steps. Genmab reported H1 2026 revenue of $2.051 billion, up 25% year-over-year, raising full-year guidance to $4.325–$4.525 billion. AbbVie posted Q2 2026 net revenues of $16.99 billion, up 10.2%, driven by its immunology portfolio generating $8.79 billion.

Yahoo Finance
Aug 6th, 2026
Genmab raises 2026 revenue guidance to $4.4B despite shares falling 2.6%

Genmab reported first-half 2026 revenue of $2.05 billion, up 25% year-on-year from $1.64 billion, though shares fell 2.6% following the announcement. The Danish biotechnology company's growth was driven by higher DARZALEX and Kesimpta royalties and increased EPKINLY net product sales. Royalty revenue reached $1.71 billion, up 24% from $1.38 billion. Global net sales of EPKINLY/TEPKINLY surged 48% to $312 million from $211 million. Adjusted operating profit increased to $656 million from $554 million in the prior-year period. Genmab raised its full-year 2026 revenue guidance to a range of $4.33 billion to $4.53 billion, up from the previous range of $4.07 billion to $4.40 billion.